Research ExplorerPublicationsExpression of MAGE-A cancer/testis antigens in esophageal sq...

Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas

Standard

Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. / Haier, J; Owzcareck, M; Guller, U; Spagnoli, G C; Bürger, H; Senninger, N; Kocher, Th.

In: ANTICANCER RES, Vol. 26, No. 3B, 11.07.2006, p. 2281-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Haier, J, Owzcareck, M, Guller, U, Spagnoli, GC, Bürger, H, Senninger, N & Kocher, T 2006, 'Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas', ANTICANCER RES, vol. 26, no. 3B, pp. 2281-7.

APA

Haier, J., Owzcareck, M., Guller, U., Spagnoli, G. C., Bürger, H., Senninger, N., & Kocher, T. (2006). Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. ANTICANCER RES, 26(3B), 2281-7.

Vancouver

Haier J, Owzcareck M, Guller U, Spagnoli GC, Bürger H, Senninger N et al. Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. ANTICANCER RES. 2006 Jul 11;26(3B):2281-7.

Bibtex

@article{cfd4c513ab9141f9b8c9ee2a34788379,
title = "Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas",
abstract = "BACKGROUND: Although the diagnosis and therapy of esophageal cancer have improved over the past decade, the prognosis remains dismal. Since MAGE-A cancer/testis antigens (CTA) are potential targets for immunotherapy, this study was aimed at evaluating their expression in these patients and its prognostic value.MATERIALS AND METHODS: Using 57B monoclonal antibody, MAGE-A CTA expression was analyzed in paraffin-embedded tumor specimens of 98 patients with esophageal squamous cell carcinoma or adenocarcinomas who had undergone surgical resection. For all patients, a postoperative follow-up of at least 4 years was available. The expression was quantified using a scoring system considering intensity and homogeneity of the immunostaining. The prognostic relevance of MAGE-A expression was analyzed in univariate analyses as well as Cox proportional hazard regression analysis.RESULTS: 57B positivity could be detected in 38 tumors (38.8%). Positive staining was observed in five out of 32 adenocarcinomas (15.2%) and in 33 out of 66 (50%) squamous cell carcinomas. MAGE-A expression did not correlate with the TNM classification, grading or age of the patients. Both univariate (p=0.88) and multivariate analyses (p = 0.82) revealed that MAGE-A expression lacked prognostic significance in esophageal carcinomas.CONCLUSION: MAGE-A was expressed in half of the squamous cell carcinomas of the esophagus, but rarely in adenocarcinomas. Although its immunodetection was insufficient for prognostic evaluation, the high expression rate suggests MAGE-A as a potential target for immunotherapy in the first group with the ability for pretherapeutic testing.",
keywords = "Adult, Aged, Antigens, Neoplasm, Esophageal Neoplasms, Female, Humans, Male, Melanoma-Specific Antigens, Membrane Proteins, Middle Aged, Neoplasm Proteins, Neoplasm Staging, Neoplasms, Squamous Cell, Proportional Hazards Models",
author = "J Haier and M Owzcareck and U Guller and Spagnoli, {G C} and H B{\"u}rger and N Senninger and Th Kocher",
year = "2006",
month = jul,
day = "11",
language = "English",
volume = "26",
pages = "2281--7",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3B",

}

RIS

TY - JOUR

T1 - Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas

AU - Haier, J

AU - Owzcareck, M

AU - Guller, U

AU - Spagnoli, G C

AU - Bürger, H

AU - Senninger, N

AU - Kocher, Th

PY - 2006/7/11

Y1 - 2006/7/11

N2 - BACKGROUND: Although the diagnosis and therapy of esophageal cancer have improved over the past decade, the prognosis remains dismal. Since MAGE-A cancer/testis antigens (CTA) are potential targets for immunotherapy, this study was aimed at evaluating their expression in these patients and its prognostic value.MATERIALS AND METHODS: Using 57B monoclonal antibody, MAGE-A CTA expression was analyzed in paraffin-embedded tumor specimens of 98 patients with esophageal squamous cell carcinoma or adenocarcinomas who had undergone surgical resection. For all patients, a postoperative follow-up of at least 4 years was available. The expression was quantified using a scoring system considering intensity and homogeneity of the immunostaining. The prognostic relevance of MAGE-A expression was analyzed in univariate analyses as well as Cox proportional hazard regression analysis.RESULTS: 57B positivity could be detected in 38 tumors (38.8%). Positive staining was observed in five out of 32 adenocarcinomas (15.2%) and in 33 out of 66 (50%) squamous cell carcinomas. MAGE-A expression did not correlate with the TNM classification, grading or age of the patients. Both univariate (p=0.88) and multivariate analyses (p = 0.82) revealed that MAGE-A expression lacked prognostic significance in esophageal carcinomas.CONCLUSION: MAGE-A was expressed in half of the squamous cell carcinomas of the esophagus, but rarely in adenocarcinomas. Although its immunodetection was insufficient for prognostic evaluation, the high expression rate suggests MAGE-A as a potential target for immunotherapy in the first group with the ability for pretherapeutic testing.

AB - BACKGROUND: Although the diagnosis and therapy of esophageal cancer have improved over the past decade, the prognosis remains dismal. Since MAGE-A cancer/testis antigens (CTA) are potential targets for immunotherapy, this study was aimed at evaluating their expression in these patients and its prognostic value.MATERIALS AND METHODS: Using 57B monoclonal antibody, MAGE-A CTA expression was analyzed in paraffin-embedded tumor specimens of 98 patients with esophageal squamous cell carcinoma or adenocarcinomas who had undergone surgical resection. For all patients, a postoperative follow-up of at least 4 years was available. The expression was quantified using a scoring system considering intensity and homogeneity of the immunostaining. The prognostic relevance of MAGE-A expression was analyzed in univariate analyses as well as Cox proportional hazard regression analysis.RESULTS: 57B positivity could be detected in 38 tumors (38.8%). Positive staining was observed in five out of 32 adenocarcinomas (15.2%) and in 33 out of 66 (50%) squamous cell carcinomas. MAGE-A expression did not correlate with the TNM classification, grading or age of the patients. Both univariate (p=0.88) and multivariate analyses (p = 0.82) revealed that MAGE-A expression lacked prognostic significance in esophageal carcinomas.CONCLUSION: MAGE-A was expressed in half of the squamous cell carcinomas of the esophagus, but rarely in adenocarcinomas. Although its immunodetection was insufficient for prognostic evaluation, the high expression rate suggests MAGE-A as a potential target for immunotherapy in the first group with the ability for pretherapeutic testing.

KW - Adult

KW - Aged

KW - Antigens, Neoplasm

KW - Esophageal Neoplasms

KW - Female

KW - Humans

KW - Male

KW - Melanoma-Specific Antigens

KW - Membrane Proteins

KW - Middle Aged

KW - Neoplasm Proteins

KW - Neoplasm Staging

KW - Neoplasms, Squamous Cell

KW - Proportional Hazards Models

M3 - SCORING: Journal article

C2 - 16821603

VL - 26

SP - 2281

EP - 2287

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 3B

ER -